• Vaxxilon receives grant to develop new prophylactic vaccine pharmaceutical-technology
    August 21, 2019
    Switzerland-based synthetic vaccines firm Vaxxilon has received a funding grant from CARB-X to support the development of a prophylactic, multivalent vaccine against carbapenem-resistant Klebsiella pneumoniae (crKP).
PharmaSources Customer Service